METTL3 potentiates osteogenic differentiation of bone marrow mesenchymal stem cells via IGF2BP1/m6A/RUNX2

Objective: Maxillofacial bone defect is a critical obstacle for maxillofacial tumors and periodontal diseases. The osteogenic differentiation of bone marrow mesenchymal stem cells BMSCs is critical for maxillofacial osteogenesis and functional reconstruction. Here, our study focused on the functions and mechanism of N-6-methyladenosine during BMSCs osteogenic differentiation BMSCs.Subject and Methods: Biofunctions of BMSCs were detected using ALP activity and alizarin red S staining assays. The molecular interaction within RNA/protein was identified by RNA immunoprecipitation and/or methylation immunoprecipitation.Results: Results indicated that m(6)A 'writer' METTL3 upregulated during the osteogenic differentiation of BMSCs upon osteogenic induction. Functionally, assays' results revealed that METTL3 overexpression promoted the osteogenic differentiation of BMSC, while METTL3 knockdown repressed the osteogenic differentiation. Mechanistically, results revealed that RUNX2 mRNA was a m(6)A-methylated target by METTL3 at its 3'-UTR. Moreover, m(6)A reader IGF2BP1 recognized the m(6)A site on RUNX2 mRNA to enhance its stability.Conclusion: In conclusion, our findings revealed the novel roles of METTL3 in BMSCs osteogenic differentiation via the IGF2BP1/m(6)A/RUNX2 signaling axis of m(6)A-dependent manner, providing a potential therapeutic target for maxillofacial bone defects treatment.

Automated summary

This study revealed the critical role of METTL3 in osteogenic differentiation of BMSCs through the m(6)A/IGF2BP1/RUNX2 signaling axis. This finding provides a potential therapeutic target for maxillofacial bone defect treatment.